Introduction

Depemokimab is GSK plc's (LSE:GSK) new ultra-long-acting anti-interleukin-5 (IL-5) monoclonal antibody, and the central question for investors is straightforward: what is it, and where does it now stand with regulators? The verified answer is that depemokimab is marketed under the brand name Exdensur, and it is approved, not merely proposed. GSK has secured approvals for severe or eosinophilic asthma in the UK (15 December 2025), the United States (16 December 2025) and the European Union (17 February 2026).

Its defining feature is convenience: a twice-yearly, every-six-months subcutaneous dose. However, the regulatory picture is not uniform across a second indication. Chronic rhinosinusitis with nasal polyps (CRSwNP) is approved in the UK and EU but received a Complete Response Letter from the US Food and Drug Administration. This article examines the product, its status, dosing, covered patients, portfolio fit and the risks that remain.

What is depemokimab?

Depemokimab is an ultra-long-acting humanised anti-IL-5 monoclonal antibody of the IgG1 kappa subtype. It binds circulating interleukin-5 with high affinity, blocking IL-5 signalling and thereby reducing the production, activation and survival of eosinophils, a type of white blood cell central to type 2 inflammatory disease.

Interleukin-5 is a well-validated target in respiratory medicine, and GSK is already established in this space through mepolizumab, sold as Nucala. Depemokimab is the company's successor asset: it combines high binding affinity with an engineered, extended half-life. That engineering is what enables a maintenance dosing interval of every six months, rather than the weeks-long intervals typical of earlier anti-IL-5 therapies.

Registrational phase III evidence for asthma came from the SWIFT-1 and SWIFT-2 trials, with the CRSwNP programme supported by the ANCHOR-1 and ANCHOR-2 studies. Specific efficacy percentages are not restated here to avoid misrepresenting the underlying data, but the trial names and the mechanism are consistent across GSK, FDA and EMA sources.

What is the verified product brand?

The verified brand name is Exdensur. This has been independently confirmed against GSK's own press releases and against the European Medicines Agency and US Food and Drug Administration. It is a distinct, newly launched brand created specifically for depemokimab.

Importantly, Exdensur is not the same product as Nucala (mepolizumab), GSK's earlier anti-IL-5 medicine. They are separate brands with different molecules and different dosing schedules, so investors should not conflate the two. In the United States, the product carries the non-proprietary suffix form depemokimab-ulaa, reflecting the standard US naming convention for biologics.

A note of caution on interpreting regulatory databases: an entry in a substance index or product register evidences only that regulatory files exist for a product. Such a listing is not, by itself, proof of a new approval, a change in ownership, a commercial launch or any measure of sales success. In this case, however, formal approvals in all three regions have been separately confirmed.

What is its current approval status?

Exdensur is approved in all three major regions for asthma, but with a critical divergence on the nasal polyps indication. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Exdensur on 15 December 2025 for both severe eosinophilic/type 2 asthma in patients aged 12 and older and for CRSwNP in adults.

In the United States, the FDA approved Exdensur on 16 December 2025 for severe eosinophilic asthma in patients aged 12 and older only. The CRSwNP indication received a Complete Response Letter and is not approved; GSK has confirmed it remains in active dialogue with the FDA on that indication.

In the European Union, the European Commission granted marketing authorisation on 17 February 2026 for both severe type 2/eosinophilic asthma (12+) and CRSwNP in adults, following a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its 8-11 December 2025 meeting. Investors should therefore treat the US market as narrower than the UK and EU for now.

How does the dosing schedule differ from established biologics?

The headline commercial differentiator is dosing frequency. Exdensur is administered subcutaneously twice yearly, once every six months, for maintenance treatment. This contrasts with the more frequent schedules of established type 2 biologics.

GSK's own mepolizumab (Nucala) is dosed roughly monthly, while other class members such as benralizumab (Fasenra), reslizumab, dupilumab (Dupixent) and tezepelumab (Tezspire) are given at intervals ranging from every two weeks to every eight weeks, depending on the product and indication. Against that backdrop, a six-monthly injection is a materially reduced treatment burden.

The commercial thesis rests on this convenience: fewer injections per year may appeal to patients, prescribers and health systems. That said, it is a qualitative argument. Long-term real-world durability of a fixed six-monthly dose, and whether clinicians favour more frequent, titratable options for some patients, will determine how far convenience translates into share.

Which patients are covered by the approved or proposed indication?

For asthma, the approved population is adults and adolescents aged 12 and older with type 2 inflammation characterised by an eosinophilic phenotype, who are inadequately controlled on maximum moderate- to high-dose inhaled corticosteroids plus another maintenance controller. It is an add-on maintenance therapy, not a replacement for inhaled controller treatment, and it targets patients who remain poorly controlled despite standard care.

For CRSwNP, where approved (the UK and EU), the indication is narrower: it covers adult patients only with severe chronic rhinosinusitis with nasal polyps for whom systemic corticosteroids and/or surgery do not provide adequate disease control. It is used as add-on therapy alongside intranasal corticosteroids.

Two distinctions matter. First, the asthma indication extends to adolescents from age 12, whereas CRSwNP is adults-only. Second, indications must not be merged across regions: the US label covers asthma only, so the CRSwNP population is not addressable in the United States under current authorisations.

How does it fit into GSK's respiratory portfolio?

GSK positions depemokimab within its Specialty Medicines and Respiratory-Immunology franchise as a next-generation, twice-yearly successor to Nucala (mepolizumab). It is a direct, wholly owned GSK asset: there is no disclosed joint venture or in-licence, and it is not a ViiV or Haleon product. GSK plc holds the marketing authorisations directly, with GlaxoSmithKline LLC as the US BLA holder.

Strategically, Exdensur extends GSK's long-standing leadership in the anti-IL-5 mechanism. The company can leverage established prescriber relationships and disease-area expertise built through mepolizumab, potentially easing market access for the newer molecule.

The flip side is internal overlap. Because Exdensur addresses a similar patient population to Nucala, some switching between the two GSK products is plausible. Whether the franchise grows overall, or simply shifts revenue from one brand to another, is a key question for the respiratory business over the medium term.

What is the addressable market and competitive landscape?

Severe eosinophilic asthma and CRSwNP are meaningful specialty markets, and the type 2 biologic class is well established and competitive. Precise market-size and peak-sales figures are not drawn from any primary GSK disclosure and are therefore not stated here; the opportunity is discussed qualitatively.

Competition is intense. Beyond GSK's own Nucala, the field includes benralizumab (Fasenra) from AstraZeneca, reslizumab from Teva, dupilumab (Dupixent) from Sanofi and Regeneron, tezepelumab (Tezspire) from AstraZeneca and Amgen, and omalizumab (Xolair) from Novartis and Genentech. Several of these, notably Dupixent and Xolair, also address CRSwNP.

Exdensur's differentiation is dosing convenience rather than a claim of superior mechanism. Growth drivers may include the six-monthly schedule, GSK's commercial infrastructure, and pending regulatory filings in additional markets such as China and Japan. Commercial performance will depend on reimbursement decisions, real-world uptake and how rivals respond.

What risks remain?

The most immediate risk is the US CRSwNP setback. The FDA's Complete Response Letter means that indication is not approved in the United States, narrowing the US addressable market relative to the UK and EU. Resolution depends on GSK's ongoing dialogue with the agency, the outcome of which is not guaranteed.

Cannibalisation of GSK's own Nucala franchise is a structural risk, as is intense competition from Dupixent, Fasenra, Tezspire and others. Reimbursement and health technology assessment outcomes, including any NICE appraisal in the UK, could shape uptake and pricing across Europe.

Further considerations include the long-term safety and efficacy durability of a fixed six-monthly biologic in routine practice, and regulatory execution risk on outstanding filings in other markets. Finally, given the December 2025 and February 2026 launch timing, no Exdensur product-level revenue is separately disclosed in GSK reporting to date, so early commercial traction cannot yet be assessed from company figures. Investors may monitor future results, label developments and HTA decisions.

Information verified as at: 14 July 2026, 5:00 pm (UK time, BST). This article is for information only and does not constitute investment advice or a recommendation to buy, sell or hold any security, nor medical advice.